""WATCH ME GROW PEDIATRICS, LLC""
3586 ALOMA AVE STE 2
Colorado
United States
John Jesitus is a medical writer based in Westminster, CO.
November 27, 2020
Genetic polymorphisms may increase psoriasis susceptibility, according to a study that found patients who have the G allele in the JAK1 gene have twice the risk of developing psoriasis, and for those with the JAK3 allele, the risk rises nearly 2-fold.
November 24, 2020
New study data shows that in adults with atopic dermatitis, dupilumab has performed as expected, with continued efficacy and no new safety signals.
November 13, 2020
A variety of new vehicles designed to improve tolerability and cosmetic acceptability are providing rosacea patients with multiple viable treatment options.
November 11, 2020
In a recent study, psoriasis drugs showed widely variable drug survival rates, owing to differences in safety, efficacy, patient satisfaction and other factors. However, concerns linger over potential to cause long-term cumulative organ toxicity.
November 10, 2020
Comorbidities, co-medication, organ impairment, functional deterioration and frailty make treatment plans challenging for older psoriasis patients. However, these patients should not be precluded but will require more extensive evaluation and assessment, according to a recent study.
November 04, 2020
Joel Schlessinger, M.D., and Adam Friedman, M.D., detail how they have adapted to teledermatology since the start of the COVID-19 pandemic.
October 27, 2020
A phase 3b study investigating the efficacy and safety of risankizumab compared to secukinumab showed positive results, with risankizumab demonstrating noninferiority to secukinumab at week 16, and superiority at week 52.
October 21, 2020
In a recent phase 3 trial, dupilumab (Dupixent, Sanofi and Regeneron) demonstrated positive results in itch reduction, skin clearance and quality-of-life. Indicating the biologic as a viable treatment option for severe atopic dermatitis in younger children.
October 20, 2020
A recent review reveals older adults are underrepresented in trials investigating systemic immunomodulators as a treatment for atopic dermatitis.
October 10, 2020
A recent study underscores the need for a consistent scale to grade risk levels of cutaneous squamous cell carcinoma (SCC), particularly poorly differentiated tumors, according to study authors who presented at the 2020 virtual American Society for Dermatologic Surgery (ASDS) meeting.
